Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05634109
Other study ID # 1938
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 14, 2023
Est. completion date January 2025

Study information

Verified date January 2023
Source Fundacion Clinica Valle del Lili
Contact Alberto F Garcia, MD MSc
Phone +576023319090
Email alberto.garcia@fvl.org.co
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate among trauma patients with hemorrhagic shock the clinical impact of hemostatic resuscitation between whole blood vs. blood components therapy in the following outcomes in a hierarchical analysis: mortality at 28 days and evolution of organ dysfunction.


Description:

Background: Hemostatic resuscitation is a mainstay in the management of trauma patients. Factors such as blood loss and tissue injury contribute to coagulation and hemodynamic status imbalances. Hemorrhage remains a leading cause of death in trauma patients, despite advances in strategies such as damage control surgery, massive transfusion protocol, and intensive care. Conventional therapy for hemostatic resuscitation is a blood transfusion seeking a 1:1:1 ratio of red blood cells, plasma, and platelets. However, this ratio has disadvantages in clinical practice, especially in low-resource settings. Whole blood transfusion can contribute to maintaining a physiological rate of cells, clotting factors, and hemostatic properties. Advances in the whole blood elucidated a new opportunity for its implementation in civilian trauma centers. However, the effect of initial resuscitation with whole blood in trauma patients is unclear. This study aims to determine the effect of hemostatic resuscitation using whole blood on mortality and evolution of organ dysfunction in severe trauma patients compared to blood components therapy. This clinical trial attempts to resolve the debate and uncertainty of using whole blood vs. blood components. Study Design: An open-label, randomized, prospective, single-center and controlled trial will be performed. This study will be included prospectively randomized severe trauma patients who require a blood transfusion. Randomization can assign participants to the experimental arm, transfusing them with 3 units of whole blood. If the participant continues requiring transfusions, the second intervention of 3 units of whole blood can be administered. On the contrary, the randomization can assign to the control arm, where the participant will receive 3 red blood cell units, 3 fresh frozen plasma units, and half of a platelets apheresis, equivalent to 3 platelets units. If required, a second intervention with the same ratio can be transfused to participants. The primary outcome is a hierarchical composite outcome based on mortality at 28 days and the evolution of organ dysfunction. Organ dysfunction will be measured as the difference in the score between the fifth and first days of the SOFA (Sequential Organ Failure Assessment). Secondary outcomes are mortality, coagulopathy profile, intensive care unit free days, length of hospital stay free days, and volumes of transfusion requirements. Safety outcomes are complications related to transfusion (anaphylaxis, acute hemolytic reaction, acute lung injury) and complications related to trauma patients (acute distress respiratory syndrome, pulmonary embolism, deep vein thrombosis, acute kidney injury with or without dialysis, stroke, myocardial infarction, cardiac arrest, sepsis, abdominal complications, abdominal compartment syndrome)


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date January 2025
Est. primary completion date February 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (> 18 years) - Activating institutional trauma code for trauma patients with hemorrhagic shock. - Candidate for massive transfusion (Patient with an Assessment Blood Consumption (ABC) Score = 2 or at the discretion of the treating physician) - Concurrent availability of whole blood or blood component therapy Exclusion Criteria: - More than 4 hours from trauma to hospital admission - More than 2 hours from hospital admission to randomization - Transfusion of more than one packed red blood cell unit prior to randomization. - Patients who have undergone surgery (laparotomy, thoracotomy, or sternotomy) before hospital admission. - In-extremis patients with devastating injuries (expected to die within 60 minutes). - Blood group other than to O or A and positive Rh factor - Severe traumatic brain injury in which neurosurgical intervention is futile (partial decapitation, massive intracranial hemorrhage, or transcranial gunshot wounds). - Burns over 20% of the total body surface area. - Suspected airway burn. - Cardiopulmonary resuscitation (CPR) before arrival at the ED. - CPR for more than 5 minutes before randomization. - Do not resuscitate order. - Incarcerated/prisoners. - Known pregnancy in the ED. - Patient or legal representative who refuse to participate in clinical research studies.

Study Design


Intervention

Biological:
Transfusion of blood products
The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.

Locations

Country Name City State
Colombia Fundacion Clinica Valle del Lili Cali Valle Del Cauca

Sponsors (3)

Lead Sponsor Collaborator
Fundacion Clinica Valle del Lili Hospital Universitario del Valle Evaristo Garcia, University of Pittsburgh

Country where clinical trial is conducted

Colombia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome is a hierarchical outcome consisting of mortality at 28 days post-randomization and evolution of organ dysfunction (difference of Sequential Organ Failure Assessment (SOFA) score between day 1 and day 5 post-randomization). The primary outcome is a hierarchical composite outcome that will be analyzed using the Win-Ratio test. The first level will be 28-day mortality. The "winner" will be the participant who survival; in case of a tie, the second level will be the difference in SOFA score between fifth and first day. The "winner" will be participant with the lowest difference. 28 days post ED admission
Secondary 24-hour mortality The occurrence of deaths in the first 24 hours post-ED admission and we will document and record the time of death in hours. First 24 hours post ED admission.
Secondary In-hospital mortality The occurrence of deaths during the hospital stays post-ED admission, and we will document and record the time of death in days. 28 days post ED admission
Secondary Multiple organ dysfunction incidence Multiple organ dysfunction is a score = 3 in two or more systems evaluated by SOFA score. 1-day / 3-day / 5-day / 7-day post-ED admission
Secondary Evolution of Coagulopathy We will evaluate the values of INR, fibrinogen, and MA-TEG during the admission and the first 24 hours post-ED admission. Admission - 3 hours - 6 hours - 24 hours post-ED admission
Secondary Intensive care unit-free days ICU-free days 28-days post-ED admission
Secondary Hospital length stay-free days Hospital length stay-free days 28-days post-ED admission
Secondary Blood transfusion requirements during the first 24 hours The number of units of whole blood or blood components transfused. Comparisons will be according to the following references:
1 Unit of Whole blood = 1 Unit of packed red blood cells.
1 Unit of Whole Blood = 1 Unit of Plasma
1 Unit of Whole Blood = 1 Unit of Platelets
Time frame 3 hours / 6 hours / 12 hours / 24 hours
Secondary Proportion of participants with transfusional adverse reactions We will document transfusional adverse reactions such as acute hemolytic reaction, anaphylaxis, non-hemolytic febrile transfusion reaction, allergy, and potassium and calcium electrolyte disorders. 28-days post-ED admission
Secondary Proportion of participants with adverse reactions We will document adverse reactions such as acute lung injury, acute respiratory distress syndrome, pulmonary embolism, deep vein thrombosis, acute kidney injury with or without dialysis, stroke, myocardial infarction, cardiac arrest, sepsis, abdominal complications, and abdominal compartment syndrome 28-days post-ED admission
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4